Genomic Revolution
Gene editing, personalized medicine, and genomics transforming healthcare through precision treatments and genetic insights.
Key Public Companies - Live Stock Data
CRISPR Clinical Success
First CRISPR gene editing treatments approved for sickle cell disease and beta-thalassemia, proving clinical viability of gene editing.
Genomic Sequencing Cost Decline
Whole genome sequencing costs have dropped from $100M in 2001 to under $1,000 today, enabling widespread adoption.
Pharmacogenomics Integration
Genetic testing is becoming standard for drug prescribing, with 200+ FDA-approved pharmacogenomic biomarkers.
Newborn genome sequencing becomes standard healthcare
Preventive medicine based on genetic predisposition becomes norm
Gene editing treats common diseases like diabetes
Shift from symptom management to genetic cure approaches
Personalized medicine reaches 50% of treatments
Healthcare becomes truly individualized based on genetic profiles
Gene Editing Companies
CRISPR and other gene editing technology developers
Genomic Sequencing
DNA sequencing technology and service providers
Precision Medicine
Personalized treatment platforms and diagnostic companies
- Base editing and prime editing advances
- In vivo gene editing delivery systems
- Polygenic risk scores for disease prediction
- Epigenetic editing technologies
- Gene drives for disease vector control
- Ethical concerns around genetic modification
- Regulatory approval complexity
- High development and treatment costs
- Off-target effects and safety concerns
- Equitable access to genetic therapies
Illumina Inc.
Leading DNA sequencing technology company enabling genomic research
CRISPR Therapeutics
Gene editing company developing CRISPR-based therapies
Editas Medicine
Clinical-stage gene editing company using CRISPR technology
Prime Medicine
Next-generation gene editing company developing prime editing technology
Mammoth Biosciences
CRISPR-based diagnostics and therapeutics platform company
Ready to Invest in Genomic Revolution?
Join thousands of investors who are already building wealth through strategic investments in genomic revolution. Start your investment journey today with our expert-curated opportunities.